Mizuho Lowers Leap Therapeutics (NASDAQ:LPTX) Price Target to $2.00

Leap Therapeutics (NASDAQ:LPTX – Get Rating) had its target price lowered by research analysts at Mizuho from $3.00 to $2.00 in a report released on Friday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s price objective would suggest a potential upside of 449.15% from the company’s current price.

Several other research analysts have also recently issued reports on LPTX. HC Wainwright reduced their price objective on Leap Therapeutics from $4.00 to $2.50 and set a “buy” rating for the company in a research note on Wednesday, January 18th. Piper Sandler reduced their price objective on Leap Therapeutics from $4.00 to $3.00 in a research note on Tuesday, January 17th. Finally, Robert W. Baird reduced their price objective on Leap Therapeutics to $4.00 in a research note on Monday, November 21st.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.36 on Friday. The company has a market cap of $36.06 million, a PE ratio of -0.77 and a beta of 0.75. The business has a 50-day simple moving average of $0.57 and a two-hundred day simple moving average of $0.71. Leap Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $1.95.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its position in Leap Therapeutics by 44.2% during the second quarter. Virtu Financial LLC now owns 28,865 shares of the company’s stock valued at $33,000 after acquiring an additional 8,852 shares in the last quarter. Private Advisor Group LLC raised its position in Leap Therapeutics by 104.5% during the first quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock valued at $39,000 after acquiring an additional 11,500 shares in the last quarter. BlackRock Inc. raised its position in Leap Therapeutics by 1.2% during the first quarter. BlackRock Inc. now owns 1,198,188 shares of the company’s stock valued at $2,098,000 after acquiring an additional 14,079 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Leap Therapeutics during the first quarter valued at approximately $26,000. Finally, Silverarc Capital Management LLC raised its position in Leap Therapeutics by 1.8% during the first quarter. Silverarc Capital Management LLC now owns 1,032,163 shares of the company’s stock valued at $1,806,000 after acquiring an additional 18,499 shares in the last quarter. 37.44% of the stock is currently owned by hedge funds and other institutional investors.

Leap Therapeutics Company Profile

(Get Rating)

Leap Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR.